The aim of our study was to describe the prevalence of sarcopenia in a cohort of HIV-infected patients.
We also looked for related factors for sarcopenia in this population.
Sarcopenia is defined as an age-associated loss of skeletal muscle mass and function 1 It has been related to higher mortality in general population as well as in HIV-infected patients 2 .
Indeed, sarcopenia is a marker of frailty in the elderly.
321 HIV-infected patients were included. General and biochemical features are shown in table 1 and 2.
1. Sarcopenia is a frequent condition in HIV-infected patients despite the young age, affecting to 23.5% of our population.
2. Increased 25-OH-vitamin D levels and increased body fat mass may protect from it.
3. Clinical studies on vitamin D supplementation for sarcopenia prevention in HIV-infected patients are warranted.
POSTER NO 126. CALCIUM AND VITAMIN D METABOLISM.
Skeletal muscle mass (SMM), total fat mass and body fat distribution were measured by DXA scan.
Muscle mass index (MMI) was calculated as described: lower limb SMM/height 2.
Sarcopenia was defined as an MMI <2 SD from observed in general population 3 -7.26 Kg/m 2 in males,
-5.5 Kg/m 2 in females.
Body fat distribution was determined by body fat index: trunk fat mass divided by limb fat mass.
This index is used in to define lypodistrophy in HIV infected patients.
Plasma levels of 25-OH-vitamin D (VD) were measured by immunoassay.
Hypovitaminosis D was described as 25-OH-VD levels <30 ng/mL. ART:a ntiretrvi ra l trea tment: HCV: hepa titis C vi rus ; BMI: body,ma s s i ndex. 77% of our HIV-infected patients had low levels of 25-OH-VD (<30 ng/mL), being 10% of all severe deficient (<10 ng/mL) (figure 2). We found a prevalence of sarcopenia in our patients of 23,5%. Loss of muscle mass was related to lower BMI, lower waist circunference and lower body fat. After adjusting for age, gender, CD4 count and treatment, plasma levels of 25-OH-VD (OR 0,27 [IC95% 0,08-0,89], p=0,032), and total body fat (OR 0,93 [IC95% 0,88-0,98], p=0,008) remained related to sarcopenia (Table 3) . 
